Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

471.00INR
23 Apr 2014
Price Change (% chg)

Rs6.10 (+1.31%)
Prev Close
Rs464.90
Open
Rs464.00
Day's High
Rs483.05
Day's Low
Rs464.00
Volume
561,086
Avg. Vol
679,166
52-wk High
Rs505.00
52-wk Low
Rs253.95

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 1.35
Market Cap (Mil.): Rs197,048.50
Shares Outstanding (Mil.): 423.81
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 33.12 33.26
EPS (TTM): -23.92 -- --
ROI: -13.83 19.69 18.95
ROE: -26.67 20.39 19.72
Search Stocks

MARKET EYE -Indian shares seen opening lower on profit taking after life-highs

* Indian shares are set to open lower on Thursday on profit taking after life-highs in the previous session. * NSE index futures traded on the Singapore Exchange drop 0.3 percent to 6,825, a 29-point premium to the underlying NSE index close on Wednesday, while the MSCI-Asia Pacific excluding Japan index gains 0.12 percent. * Asian shares look to extend recent solid gains on Thursday after minutes of the Federal Reserve's latest policy meeting suggested the Fed may be more cautious towards rai

10 Apr 2014

Europe's regulator to inspect Ranbaxy's India plant in June

MUMBAI - Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions.

10 Apr 2014

India regulator examines Sun, Ranbaxy merger trading: source

MUMBAI - India's market regulator will ask Ranbaxy Laboratories and Sun Pharmaceutical Industries for more information about their planned $3.2 billion merger and seek trading data from stock exchanges after shares in Ranbaxy surged in the run-up to the deal, a senior source at the regulator said on Wednesday.

09 Apr 2014

Europe's regulator to inspect Ranbaxy's India plant in June

MUMBAI - Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions.

09 Apr 2014

Europe's regulator to inspect Ranbaxy's India plant in June

MUMBAI, April 9 - Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions.

09 Apr 2014

SEBI examines Sun, Ranbaxy merger trading - source

MUMBAI - The Securities and Exchange Board of India (SEBI) will ask Ranbaxy Laboratories and Sun Pharmaceutical Industries for more information about their planned $3.2 billion merger and seek trading data from stock exchanges after shares in Ranbaxy surged in the run-up to the deal, a senior source at the regulator said on Wednesday.

09 Apr 2014

UPDATE 2-India regulator examines Sun, Ranbaxy merger trading - source

* SEBI to ask Sun Pharma, Ranbaxy for information on merger

09 Apr 2014

India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S.: sources

MUMBAI - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.

09 Apr 2014

Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S. - sources

MUMBAI - Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.

09 Apr 2014

UPDATE 2-India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in US -sources

* European regulator plans Ranbaxy plant inspection in June (Adds fund manager comment, European regulator comments)

09 Apr 2014

Earnings vs. Estimates

Search Stocks